Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Vasc Res ; 45(6): 529-37, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18463418

RESUMO

BACKGROUND: Therapeutic use of unfractionated heparin and low molecular weight heparins (LMWHs) is limited by hemorrhagic adverse effects. We compared the antithrombotic effect of LMW fucoidan (LMWF) and LMWH in an experimental model. METHODS: Thrombosis was induced in femoral arteries of male New Zealand White rabbits by in situ induction of endothelial apoptosis with staurosporine (10(-5)M for 30 min). Starting the day before apoptosis induction, the animals received subcutaneous LMWF (15 mg/kg), LMWH (enoxaparin 2.5 mg/kg) or saline solution (control group) twice a day for 4 days. RESULTS: The degrees of apoptosis and endothelial denudation were similar in the 3 groups. The thrombotic score was significantly lower in the LMWF group than in the LMWH and control groups (p = 0.01). Tissue factor expression was significantly lower in the LMWF group than in the control and LMWH groups (p = 0.01). The plasma concentration of tissue factor pathway inhibitor was significantly increased after LMWF injection (137 +/- 28 vs. 102 +/- 17; p = 0.01), whereas no change was observed after LMWH treatment. LMWF did not prolong the bleeding time or decrease platelet aggregation. CONCLUSIONS: LMWF appeared to be more effective than LMWH for preventing arterial thrombosis in this experimental model. LMWF also had a lower hemorrhagic risk than LMWH.


Assuntos
Artéria Femoral/efeitos dos fármacos , Fibrinolíticos/farmacologia , Heparina de Baixo Peso Molecular/farmacologia , Polissacarídeos/farmacologia , Trombose/prevenção & controle , Animais , Apoptose/efeitos dos fármacos , Coagulação Sanguínea/efeitos dos fármacos , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Artéria Femoral/metabolismo , Artéria Femoral/patologia , Fibrinolíticos/efeitos adversos , Hemorragia/induzido quimicamente , Heparina de Baixo Peso Molecular/efeitos adversos , Lipoproteínas/metabolismo , Masculino , Agregação Plaquetária/efeitos dos fármacos , Polissacarídeos/efeitos adversos , Coelhos , Estaurosporina , Tromboplastina/metabolismo , Trombose/sangue , Trombose/induzido quimicamente , Trombose/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA